[PNF ADVISORY] [01-21-22] – Additional formulation for Sambong as per DC No. 2022-0015: 250 mg tablet

[PNF ADVISORY] [09-27-21] – Inclusion of two-dose Inactivated Polio Vaccine as per DC No. 2021-0410: 0.5 mL per dose (suspension for injection) in 5 mL

[PNF ADVISORY] [09-27-21] – Inclusion of Tenofovir +Lamivudine + Dolutegravir as per DC No. 2021-0400: 300 mg + 300 mg + 50 mg (fixed-dose combination) tablet { p.45}

[PNF ADVISORY] [09-27-21] – Inclusion of Dolutegravir as per DC No. 2021-0423: 50 mg tablet { p.15}

[MRP Advisory] [08-24-21] – Poster and Booklet updated as of July 2021

[BNB/BNBi Advisory] [08-24-21] – Added RHU and Facility List for BNB/BNBi

[MRP ADVISORY] [04-23-21] – RDPMO Directory was updated

[PNF ADVISORY] [04-07-21] – Additional volume for Sodium Hyaluronate as per DM No. 2021-0158 : 0.1% (1 mg/mL), 15 mL bottle 

[PNF ADVISORY] [04-07-21] – Additional formulation for Peritoneal Dialysis Solution as per DM No. 2021-0158 : Sterile with 2.5% dextrose, 2 L and 5 L bottle/bag